Keywords: shire, mmx, mesalazine, performs, well, uc, studies

Shire's MMX mesalazine performs well in UC studies

Article | 13 November 2006

Print This

UK-based drugmaker Shire says that data from trials of its drug MMX mesalazine, a once-daily oral treatment for mild-to-moderate ulcerative ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in